Transcribed

Transcribed
  • 0.0 (0)
  • Entrepreneurship
  • Updated Monthly

Transcribed is your front-row seat to the fascinating world of biotech. Hosted by two curious minds bridging science and business, this podcast brings you insightful conversations with leading voices in biotechnology. Whether you're a student navigating STEM or business, or simply a curious listener, Transcribed delivers practical tools, career advice, and behind-the-scenes stories that make the complex world of biotech accessible and inspiring.

  1. 6d ago

    Can We Really Slow Aging? | Matt Kaeberlein on Rapamycin & Longevity

    What would it take to turn promising aging research into longer, healthier lives?Dr. Matt Kaeberlein joins Pierre Jacob and Meronn Jacob on Transcribed for a conversation about longevity science, the evidence behind rapamycin, and the personal story that helped inspire the Dog Aging Project.Matt explains how a talk at MIT drew him into aging research, why he challenges claims that get ahead of the data, and what he thinks the field needs to earn wider trust. He walks through rapamycin and mTOR, distinguishing the findings that excite him in laboratory research from the questions that remain about benefits in people.We also discuss biological age tests, the difficulty of defining healthspan, and why a clinical trial needs a clear answer to a deceptively simple question: what are we actually going to measure?The conversation closes with hard work and quality of life, followed by Matt's research wish list: companion animal longevity, epigenetic reprogramming, trials of overlooked drugs, and more room for discovery science.In this conversation:◼️ How Matt entered aging research in 2003◼️ Longevity hype, communication and scientific credibility◼️ Rapamycin, mTOR and what the evidence can tell us◼️ Dogs, family and the origins of the Dog Aging Project◼️ Biological clocks and the limits of individual test results◼️ Healthspan, lifespan and meaningful trial outcomes◼️ Working hard without losing sight of quality of life◼️ Where Matt would put research fundingRESOURCESDog Aging Project: https://dogagingproject.org/Further reading, TRIAD study design and rationale: https://doi.org/10.1007/s11357-024-01484-7Transcribed Podcast: in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.New episodes every Tuesday at 16:00 (Europe/Berlin).🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack: https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com🎵 Jingle composed by Tembeh: https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja#TranscribedPodcast #Longevity #Geroscience #Biotech00:00 Introducing Matt Kaeberlein00:22 How Matt found aging research01:58 Longevity hype and scientific credibility04:16 What would bring credible longevity into the mainstream?06:06 Rapamycin, mTOR and the limits of the evidence09:32 The personal story behind the Dog Aging Project12:36 Biological clocks: promise, marketing and uncertainty16:39 Healthspan, lifespan and what healthy aging means19:31 Why medicine still focuses on individual diseases22:35 Designing clinical trials that can answer useful questions25:22 Hard work, hustle culture and quality of life27:55 What Matt would fund with unlimited resources29:06 The promise and risks of epigenetic reprogramming29:50 Testing overlooked drugs30:36 Discovery science and exceptional aging

  2. Sep 22

    What It Takes to Make Longevity Medicine Work | Prof. Andrea B. Maier

    What does it take to turn longevity research into medicine people can rely on?Prof. Andrea B. Maier joins Pierre Jacob and Meronn Jacob on Transcribed to discuss precision geromedicine, the work of preserving health and function as we age, and the standards needed to bring this approach into wider clinical practice.Andrea explains how she approaches a first clinic visit, why a person's goals and daily life matter alongside biological measurements, and why making care accessible starts with defining what good care looks like. She also discusses the evidence behind DNA methylation clocks, her concerns about promises to cure all disease within a few years, and the difference between improving function and claiming to reverse aging completely.We finish with the people and institutions building the field: the Healthy Longevity Medicine Society, education at the NUS Academy for Healthy Longevity, and Andrea's advice on finding a mentor and an environment where you can do good work.In this conversation:◼️ What Andrea means by precision geromedicine◼️ What happens when someone visits her clinic◼️ Clinical standards and making longevity medicine more accessible◼️ DNA methylation clocks and the evidence needed for clinical use◼️ AI, longevity promises, and realistic expectations◼️ Why she co-founded the Healthy Longevity Medicine Society◼️ Training the next generation at NUS◼️ Function, aging, and finding the right mentorRESOURCES FROM THE CONVERSATIONFeatured programme: NUS Academy for Healthy LongevityAndrea's team describes the programme discussed as the Master of Science in Precision Geromedicine / Geroscience, with intakes offered every six months. For current programme names, availability, and application details, please consult the Academy's page:https://longevityacademy.sg/education/master-graduate-certificateThe page currently lists the Graduate Certificate in Healthy Longevity Medicine and progression towards a future Master in Healthy Longevity Medicine. Applications for the 2026 intake are closed; follow the page for updated intake information.Professional membership: Healthy Longevity Medicine Society (HLMS)Learn about membership and the Society's work towards standardizing global clinical practice in healthy longevity medicine:https://hlms.co/Reference paper supplied by Andrea's team:“Guidelines and recommendations on the clinical utility of DNA methylation clocks in precision geromedicine” (Maier et al.). Status supplied by the team: submitted / under review. A publication link is not yet available in the supplied reference.Transcribed Podcast: in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.New episodes every Tuesday at 16:00 (Europe/Berlin).🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack: https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com🎵 Jingle composed by Tembeh: https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja#TranscribedPodcast #Longevity #Geroscience #Biotech #AndreaMaier00:00 Introducing Prof. Andrea B. Maier00:32 Aging, health, and preserving function01:38 What is precision geromedicine?03:37 Inside Andrea's clinic06:33 Making longevity medicine more accessible08:33 Research, DNA methylation clocks, and clinical evidence10:27 Lessons from senescence research11:19 AI timelines and longevity promises13:36 Building the Healthy Longevity Medicine Society15:27 Education at the NUS Academy for Healthy Longevity16:06 Can aging be reversed?17:48 Advice for people entering the field19:29 Closing conversation

  3. Sep 15

    From Research to a Fundable Biotech Startup | Bodo Brückner

    What has to happen between a promising research paper and a biotech company someone is willing to fund? Bodo Brückner joins Pierre Jacob and Meronn Yoshiyama to explain how the Life Science Accelerator Baden-Württemberg helps teams work toward investment readiness, and what scientists need to understand when they start building a business.Bodo describes an entrepreneurship course in which students take a real scientific paper, imagine they own its intellectual property, and develop a business model to pitch. That exercise opens up a bigger discussion: who needs the technology, what risks remain, and which milestones could make it more valuable to a potential partner or investor?We also discuss his path from molecular biology to supporting startups, his view of Europe's funding challenges, and why observing needs in hospitals can be a starting point for innovation. On AI, Bodo shares both his interest in its potential and his skepticism about sweeping promises to solve biology on a short timeline.In this conversation:◼️ What an accelerator does to help life science teams become investment ready◼️ Bodo's move from research into consulting and startup support◼️ His perspective on early funding, scale-up capital, and repeat founders◼️ Teaching scientists to build a business case from a research paper◼️ Intellectual property, milestones, and reducing uncertainty◼️ AI expectations and the complexity of biology◼️ Learning from clinical needs and connecting startups with hospitals◼️ Understanding the business side without rushing out of science00:00 Welcome and introducing Bodo Brückner01:02 What does a life science accelerator do?02:53 Measuring investment readiness03:59 From molecular biology to supporting startups08:06 Europe's funding and scale-up challenge11:03 Repeat founders and building experience13:55 What Bodo looks for in founder teams15:20 Free Biotech Starter Pack15:36 Building a business from a research paper19:35 Technology, intellectual property, and milestones22:03 AI expectations meet biological complexity27:17 Competition, markets, and data across Europe28:36 Starting with needs in hospitals30:45 Advice for scientists considering entrepreneurship32:02 Learning the business side and staying curiousTranscribed Podcast: in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.New episodes every Tuesday at 16:00 (Europe/Berlin).🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack: https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com🎵 Jingle composed by Tembeh: https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja#TranscribedPodcast #Biotech #Entrepreneurship #LifeSciences

  4. Sep 8

    Longevity for Everyone: Lessons from 39 Countries | Marek Piotrowski

    A year on the road. Five continents. Thirty-nine countries. More than 100 conversations with scientists. Marek Piotrowski set out with his son to explore what it takes to live longer. One of his biggest lessons came from the relationship they built along the way. In this episode of Transcribed, Pierre and Meronn sit down with Marek to discuss his move from marketing strategy into longevity, the lessons from their father-and-son journey, and why he believes storytelling can bring the field to a much wider audience.Marek shares his five-part map of longevity, spanning everyday habits, biohacking, radical life extension, prevention, and building a movement. He also reflects on the difference between wanting more years in the future and making the most of life today, and explains why he sees a role for marketers, filmmakers, managers, and people working in AI alongside scientists. In this conversation: ◼️ Marek's view of how longevity can reach beyond a wealthy minority ◼️ His five-part framework for understanding the field ◼️ What traveling with his son taught him about tension, forgiveness, and relationships ◼️ His perspective on prevention, mindset, and choosing wellness over convenience ◼️ How father and son think differently about time and quality of life ◼️ His reflections on longevity conferences, biohacking, and the attention given to emotional well-being ◼️ Why he chose a father-and-son story as the basis for a film about longevity ◼️ Ways to contribute through science, AI, storytelling, business, and public policy Transcribed Podcast: in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.New episodes every Tuesday at 16:00 (Europe/Berlin). 🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod 📥 Free Biotech Starter Pack: https://transcribedpod.com 🌐 https://transcribedpod.com 📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com 🎵 Jingle composed by Tembeh: https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja #TranscribedPodcast #MarekPiotrowski #Longevity #Biotech #ScienceCommunication## Chapter draft (check against the final video before adding to the description) 01:14 Welcome and introducing Marek Piotrowski 01:48 Making longevity accessible: Marek's five-part map 06:28 A year with his son: the unexpected relationship lesson 08:28 Marek's perspective on prevention and health choices 11:17 Mindset and prioritizing wellness 13:42 Two generations, two perspectives on longevity 15:08 Longevity clinics, biohacking, and hype 17:06 Relationships and emotional well-being 18:29 Bringing longevity to a wider audience through film 21:07 Finding your role in longevity 23:12 Closing

  5. Sep 1

    Can We Print Human Organs? Why Cells Need a Home | Ahed Almalla

    As co-founder of Renatrix, Dr. Ahed Almalla is building a future where cells "feel at home" — using advanced biomaterials to create 3D microenvironments that better mimic human biology. In this episode, she shares her incredible journey from war-torn Aleppo to founding a biotech startup in Berlin, how she shifted from academic perfectionism to entrepreneurial action, and her vision for 3D bioprinting functional organs from a patient's own cells. Dr. Ahed Almalla is the co-founder of Renatrix, a Berlin-based biotech startup developing advanced biomaterials for 3D cell culture. A biomaterial chemist, she holds a PhD from Freie Universität Berlin, having started her scientific journey from Aleppo, Syria. Ahed is passionate about solving problems in science and building innovative solutions that bridge the gap between academic research and real-world applications. 📥 We distilled the sharpest lessons from our first 6 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.com Ahed explains: ◼️ Her journey from war-torn Aleppo to pursuing a PhD in Berlin, and how a lack of resources in Syria fueled her love for hands-on science ◼️ The "aha!" moment at a conference that made her realize her PhD research on biomaterials could be a valuable product ◼️ Why the extracellular matrix (ECM) is crucial for cell health and function, and how traditional 2D cell cultures fail to mimic natural biology ◼️ Renatrix's unique process of repurposing animal tissues from slaughterhouses to create their proprietary biomaterials ◼️ The hardest part of translating academic research into a scalable product: shifting from a mindset of "perfection" to "just do it" and adapting quickly ◼️ Her long-term vision for Renatrix: to make their ECMs the "gold standard" tool in every lab and enable the future of functional organ bioprinting for personalized medicine 00:00 Welcome to Transcribed 00:44 From Aleppo to Berlin: Ahed's Path to Science 03:15 Falling in Love with Problem-Solving and Collaborative Science 05:10 PhD Focus: 3D Bioprinting and Biomaterials 06:45 The Turning Point: From Academia to Entrepreneurship 08:10 Why the Extracellular Matrix Matters for Cell Health 09:45 The Problem with Traditional 2D Cell Cultures 11:15 Renatrix's Process: Repurposing Tissues for Science 14:10 The Hardest Part: Shifting from Academic to Startup Mindset 16:10 Advice for Aspiring Founders: Don't Wait for Perfection 17:45 How Incubators like EXIST Women Support Female Founders 19:15 Improving Female Representation in Biotech 21:10 Balancing a Startup and Family Life 23:15 Renatrix's Ideal Customer and 10-Year Gold Standard Goal 25:10 Organoids vs. Animal Models: Future of 3D Tissue Engineering 27:10 The Vision for Functional Organ Bioprinting & Personalized Medicine 29:40 Final Advice: Believe in Yourself, Just Go For It 30:30 Closing Follow Ahed: https://www.linkedin.com/in/ahedalmalla/ --- Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma. 🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod 📥 Free Biotech Starter Pack → https://transcribedpod.com 🌐 https://transcribedpod.com 📸 Instagram: @transcribedpod 📧 thetranscribedpod@gmail.com 🎵 Jingle composed by Tembeh → https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja #TranscribedPodcast #Biotech #Pharma #Science #Interview #Renatrix #Biomaterials #3DBioprinting #CellCulture #Startups #Entrepreneurship #FemaleFounders #Aleppo #Berlin #Innovation

  6. Aug 25

    The Stem Cells Nobody Wanted: A Father’s Discovery | Yuta Lee

    As a founder and CEO of Accelerated Biosciences, Yuta Lee made an unlikely leap from a career in finance and insurance to building one of the most unusual stem cell platforms in regenerative medicine. He's commercializing a cell type discovered by his own father, one that might hold the key to fighting aging at its root. In this episode, Yuta unpacks his journey from property casualty insurance to biotech, the ethical sourcing and unique power of trophoblast stem cells, and how his company aims to provide the "NVIDIA chip" for the stem cell industry, tackling diseases like Parkinson's, diabetes, and aging itself. Yuta Lee is the Founder and CEO of Accelerated Biosciences, a regenerative medicine company focused on commercializing trophoblast stem cells. He spent eight years in the finance and insurance industry before pivoting to biotech after his mother's cancer diagnosis and his father's groundbreaking stem cell discovery. Holding an undergraduate degree from Berkeley in economics and law, Yuta self-taught biology to build his company, now leading the charge in developing ethically sourced, scalable, and immune-privileged stem cell therapies. 📥 We distilled the sharpest lessons from our first 6 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.com Yuta explains: ◼️ His "unlikely leap" from 8 years in property casualty insurance to founding Accelerated Biosciences, driven by family and a personal challenge to learn biology from scratch ◼️ What trophoblast stem cells (TSCs) are, how they're uniquely sourced from ectopic pregnancies, and why they represent the earliest and most ethically clear stem cells available ◼️ The science behind cell senescence and longevity, including heterochronic parabiosis studies, and how their cells' secretome can systemically downregulate inflammation (SASP proteins) ◼️ His vision for preventative medicine, where regular injections could allow a 100-year-old to have the organs of a 23-year-old, and why current regulatory systems are the biggest bottleneck for this vision ◼️ Advice for aspiring biotech professionals: don't be afraid to learn outside formal education, as everything is available online, and how his "outsider" perspective helps simplify complex ideas 00:00 Welcome to Transcribed 00:40 Yuta's Unlikely Leap: From Finance to Biotech 02:45 Professional Differences: US vs. Taiwan 04:10 Understanding Trophoblast Stem Cells (TSCs) 06:30 Ethical Sourcing of TSC s09:30 Building a Biotech: Challenges of Manufacturing Stem Cells 13:00 The "NVIDIA Chip" of Stem Cells: Unique Characteristics of TSCs16:45 Scale & Immune Privilege: Key Advantages 19:30 Rapid Differentiation: Parkinson's & Diabetes Applications 23:00 Cell Senescence & Longevity: The Secretome Approach 26:15 Heterochronic Parabiosis & Rejuvenation 30:00 Longevity as an Engineering Problem: Yamanaka Factors vs. Parabiosis 32:10 The Vision: Preventative Medicine & Organ Rejuvenation 34:00 Advice for Personal Health & Longevity 36:00 Scaling a Biotech: Market Timing & Macro Events 38:30 The Biggest Bottleneck in Biotech: Regulatory Hurdles 42:00 The Need for a "Prevention Section" in Regulation 44:00 Advice for Aspiring Biotech Professionals: Learn Beyond Formal Education 46:00 Closing --- Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma. 🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod 📥 Free Biotech Starter Pack → https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com 🎵 Jingle composed by Tembeh → https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja #TranscribedPodcast #Biotech #Pharma #Science #Interview #YutaLee #AcceleratedBiosciences #StemCells #RegenerativeMedicine #Longevity #Aging #FinanceToBiotech #TrophoblastStemCells #Parkinsons

  7. Jun 30

    Building Life from Scratch with DNA Origami | Kerstin Göpfrich

    Welcome back to Transcribed, the podcast where we unpack the minds building the future of biotech. Today's guest, Professor Dr. Kerstin Goepfrich, is asking one of the most fundamental questions in all of science: what is life, and can we build it from scratch? As a full professor at Heidelberg University and group leader at the Max Planck Institute for Medical Research, she is one of the world's leading voices in synthetic biology and DNA nanotechnology. Her work shows that DNA is an extraordinary building material, engineering structures that mimic the machinery of living cells — cytoskeletons, contractile rings, nanopores built from the ground up, one molecule at a time. Understanding life means being able to recreate it, and that's exactly what she's working towards. Professor Dr. Kerstin Goepfrich is a Full Professor at the Center for Molecular Biology at Heidelberg University and a Group Leader at the Max Planck Institute for Medical Research. She studied physics and molecular medicine in Erlangen, an unusual combination that shaped her interdisciplinary approach to biology. Her lab focuses on bottom-up synthetic biology, using DNA and RNA as building blocks to create minimal, self-replicating, evolving entities. 📥 We distilled the sharpest lessons from our first 6 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.com Kerstin explains: ◼️ How her unusual background in physics and molecular medicine led her to seek a "deeper understanding of the world" and tackle big questions like "what is life?" ◼️ Why DNA is an "extraordinary building material" beyond information storage, enabling complex 3D structures like the iconic DNA origami smiley face ◼️ The challenges of RNA folding compared to DNA, and why RNA is crucial for building synthetic cells due to its ability to store information *and* execute function ◼️ The breakthrough of building a genetically encoded, evolvable RNA cytoskeleton from scratch, moving towards systems that can "create complexity by itself" ◼️ Her realistic timeline for creating a "very minimal self-replicating evolving entity" in the lab — and the hardest unsolved problem of integrating genes into genomes ◼️ The immediate applications of synthetic biology tools, from enhancing RNA therapeutics and aptamers to engineering synthetic immune factors and CO2-capturing cells ◼️ Her philosophical perspective on "what is life," viewing it as a continuum from non-life to increasing complexity, rather than a black-and-white definition 00:00 Welcome to Transcribed 00:44 What is Life? Building it from Scratch 01:40 Physics, Molecular Medicine & the Quest for Deeper Understanding 03:00 From Studying to Building: The Path to Synthetic Biology 04:30 The Origins of Bottom-Up Synthetic Biology 05:50 DNA: More Than Information Storage — An Extraordinary Building Material 07:40 The Challenges & Promise of RNA Origami 10:30 Building a Genetically Encoded RNA Cytoskeleton 13:00 The Risks & Biocontainment of Synthetic Life 14:00 AI, AlphaFold & the Future of RNA Folding 17:30 When Will We Build a Self-Replicating Synthetic Cell? 19:30 The Hardest Unsolved Problem in Synthetic Cell Research 21:00 From Science Fiction to Reality: Applications of Synthetic Cells 25:00 Curiosity-Driven Research vs. Application-Focused Science 27:00 The Philosophy of Life: A Continuum of Complexity 30:00 Life Beyond Earth: Carbon-Based or Something Else? 32:00 Advice for Young Scientists in Synthetic Biology 34:00 Closing --- 🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack → https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com 🎵 Jingle composed by Tembeh → https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja #KerstinGoepfrich #TranscribedPodcast #Biotech #Pharma #Science #Interview #SyntheticBiology #HeidelbergUniversity #Goepfrich #DNAOrigami #RNATherapeutics #Kerstin

  8. Jun 18

    Europe Has the Science. Where’s the Biotech Investment? | Siegfried Bialojan

    After four decades at the intersection of science, industry, and strategy — from the DKFZ bench to 14 years in pharma R&D to two decades writing the EY Biotech Report — Dr. Siegfried Bialojan has watched German biotech ask the same question for 25 years: why doesn't the money show up? In this episode, he explains why Germany has never built a venture capital culture, the Strüngmann bet on BioNTech that nobody else would take, and the uncomfortable pattern of German innovation being acquired by foreign capital before it ever reaches the market. Dr. Siegfried Bialojan is the former Executive Director of the EY Life Sciences Center in Mannheim and the author of the German EY Biotech Report, the most cited annual snapshot of the German biotech industry. Trained in molecular biology and medicine, he spent 14 years in pharma R&D at BASF (including the lab next door to where Humira was discovered) before joining EY in 2001 to build its life sciences practice — what he calls his "yellow parrot" years as a scientist among economists. 📥 We distilled the sharpest lessons from our first 8 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.com Siegfried explains:◼️ Why Germany has the science but not the mindset — "no risk, no fun" and the cultural gap that keeps capital out of biotech◼️ The Strüngmann bet on BioNTech: how a single private family office took the mRNA risk that no VC or pharma would touch, and why that example should reshape how Germany thinks about early funding◼️ The Baden-Württemberg leverage model — two euros of state money for every private euro — and why it actually moves the needle on early-stage risk◼️ Why German innovation keeps getting acquired before it reaches the market (Tubulis is the latest), and what the country loses each time it happens◼️ Career advice from someone who pivoted three times: don't wait for job boards, talk to people directly, and carry your competence forward rather than starting from scratch 00:00 Welcome to Transcribed00:48 Inside EY: From Audit Firm to Biotech Thought Leader01:19 The "Yellow Parrot" Years — A Scientist Among Economists05:31 Building the EY Life Sciences Center in Mannheim08:11 Before Google: How to Collect Biotech Data via Questionnaires10:14 From the DKFZ Bench to BASF — Why He Left Academia12:55 The BASF–Abbott Sale and the Humira Lab Next Door14:33 Spotting Career Opportunities: Bring Your Competence Forward17:48 Advice for Scientists Moving from Academia to Industry22:00 Why Direct Outreach Beats 200 Job Applications24:00 Learning Finance as a Scientist Inside EY25:24 Two Decades of Biotech Reports: Why the Same Problems Keep Coming Back27:00 The Risk-Taking Gap — Why Germany Doesn't Own Stocks32:00 The Strüngmann Bet on BioNTech: When Private Money Beats VC36:33 Where the Money Is Really Needed (and Why VCs Show Up Too Late)39:30 The Baden-Württemberg Model — Leveraging Private Money with State Money43:00 The 1% Pension Fund Idea: What Switzerland Did and Germany Didn't45:39 Germany vs US vs China — Where the Money (and the Exits) Go48:00 Tubulis and the German Innovation Drain50:00 Advice to Young Biotech Scientists Today51:13 Closing Follow Siegfried:LinkedIn - https://www.linkedin.com/in/siegfried-bialojan-64958113/ --- Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma. 🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack → https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com 🎵 Jingle composed by Tembeh → https://open.spotify.com/artist/4s9JmadJjVdYQ6YxYtJgja #TranscribedPodcast #Biotech #Pharma #Science #Interview #VentureCapital #BioNTech #GermanBiotech #EY #LifeSciences #Heidelberg

See All (16)

About

Transcribed is your front-row seat to the fascinating world of biotech. Hosted by two curious minds bridging science and business, this podcast brings you insightful conversations with leading voices in biotechnology. Whether you're a student navigating STEM or business, or simply a curious listener, Transcribed delivers practical tools, career advice, and behind-the-scenes stories that make the complex world of biotech accessible and inspiring.

Information

  • Creator
    Transcribed
  • Years Active
    2025 - 2026
  • Episodes
    16
  • Rating
    Clean
  • Copyright
    © Transcribed
  • Show Website
    Transcribed